Roberto A. Cid-Pazo - Publications

Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 03, 2026

Real-World Germline Testing Patterns and Clinical Implications of HRR-Associated Germline Variants in Pancreatic Ductal Adenocarcinoma.

Journal: Cancers

Published: June 29, 2026

Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5%: a post hoc, exploratory, long-term follow-up of RATIONALE-306☆.

Journal: ESMO open

Published: February 17, 2026

Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 04, 2025

Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 24, 2025

Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.

Journal: Advances in therapy

Published: August 13, 2025

SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 17, 2025

Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 10, 2025

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1.

Journal: Cell reports. Medicine

Published: February 21, 2025

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial.

Journal: ESMO open

Published: February 18, 2025

A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3).

Journal: Future oncology (London, England)

Published: February 12, 2025